Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESBA105 in Severe Dry Eye
NCT01338610Phase 2
Key facts
- Status
- Completed
- Start
- Jun 2011
- Primary completion
- Feb 2012
- Countries
- 1
- Sponsor
- Alcon Inc.
- Modality
- Antibody Conjugates, scFv Fragments, Monoclonal Antibodies
- Drugs
- DLX105
- Conditions
- dry eye disease (DED)
01
Overview
Phase 2, randomised, double-blind trial in dry eye disease (DED) comparing ESBA105 with Vehicle (2 arms). Primary endpoint: Visual Analog Scale (VAS) Global Ocular Discomfort Score, Area Under the Curve. Started Jun 2011; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
ESBA105
ESBA105 ophthalmic solution, 1 drop in each eye 3 times per day
Vehicle
ESBA105 vehicle, 1 drop in each eye 3 times per day
03
Who it enrols
Patients with ongoing dry eye for at least 6 months using artificial tears and experiencing persistent discomfort.
04
Endpoints
Primary
Visual Analog Scale (VAS) Global Ocular Discomfort Score, Area Under the Curve
Beyond the preview
Go deeper on NCT01338610.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01338610.